These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 1648791)

  • 1. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs and herbal remedies that affect blood clotting.
    Wynn RL; Bergman SA
    Gen Dent; 2002; 50(6):484-8, 490. PubMed ID: 12572177
    [No Abstract]   [Full Text] [Related]  

  • 4. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thrombin].
    Camici M; Sagripanti A; Di Mitri R
    Minerva Med; 2000; 91(5-6):105-12. PubMed ID: 11084844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct thrombin inhibitors (part 1 of 2).
    Arora UK; Dhir M
    J Invasive Cardiol; 2005 Jan; 17(1):34-8. PubMed ID: 15640538
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion.
    Basic-Micic M; Breddin HK
    Semin Thromb Hemost; 1993; 19 Suppl 1():22-8. PubMed ID: 8395725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
    Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
    Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
    Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombin and heparin cofactor II-mediated inactivation of alpha-thrombin by a synthetic, sulfated mannogalactan.
    Gracher AH; Cipriani TR; Carbonero ER; Gorin PA; Iacomini M
    Thromb Res; 2010 Sep; 126(3):e180-7. PubMed ID: 20553946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical studies on sulfated lactobionic acid amides.
    Klauser RJ; Meinetsberger E; Raake W
    Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparin in surgery and artificial circulation: pro and contra. Is there an alternative?].
    Roĭtman EV; Dement'eva II; Meshcheriakov AV
    Anesteziol Reanimatol; 1997; (6):65-9. PubMed ID: 9511253
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects.
    Saivin S; Petitou M; Lormeau JC; Dupouy D; Sié P; Caranobe C; Houin G; Boneu B
    Thromb Haemost; 1992 Mar; 67(3):346-51. PubMed ID: 1322569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.